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ABSTRACT  Epidermal  growth  factor (EGF), circulating in the  blood,  is taken  up  by rat  liver 
hepatocytes by means of specific and saturable  receptor-mediated endocytosis. These exper- 
iments were undertaken to determine (a) the transport pathway(s) of EGF taken up by rat liver 
and (b) the effects of lysosomal  inhibition on its transport. 1251-EGF  was injected into rat portal 
veins,  and bile samples were collected and analyzed for both total and immunoprecipitable 
radioactivity. In addition, the livers were examined by electron microscopic autoradiography. 
Some animals received injections of chloroquine before surgery, to disrupt lysosomal function. 
The results  indicate that most of the  EGF taken  up  by the hepatocytes is transported  to 
lysosomes and degraded. However, a small but significant percentage of endocytosed EGF is 
transported by a pathway independent of the lysosomal system, resulting in secretion of intact 
EGF: (a) Both degraded and immunoprecipitable  EGF are secreted into bile.  (b) Immunopre- 
cipitable  radioactivity  peaks at 20 min  after  EGF  injection, whereas degradation-associated 
radioactivity does not peak until 40 min postinjection. (c) EGF isolated from bile is specifically 
taken up by isolated hepatocytes in monolayer culture, indicating that it is still  recognizable 
by the EGF receptor. (d) When the lysosomal  system is inhibited with chloroquine, secretion 
of degraded  EGF is significantly  inhibited, whereas the amount of intact EGF secreted  into 
bile is unchanged. 
The utilization by liver of a dual transport process for EGF represents an unusual system of 
intracellular ligand  processing,  whose physiological significance  has yet to be determined. 
Epidermal growth factor (EGF), ~ a  small (-6,400  mol wt) 
peptide originally found in salivary and Brunner's glands, has 
been shown to have a variety of effects on the gastrointestinal 
tract (1).  Recent experiments in this and other laboratories 
have demonstrated that rat hepatocytes, by means of specific 
(2) and saturable (3) receptor-mediated endocytosis, take up 
EGF  from  plasma  and  secrete  it  into  bile  (2).  By  using 
autoradiography, we showed that endocytosed EGF formed a 
steep portal to central lobular concentration gradient in the 
liver (2).  Immunoprecipitation of bile collected after EGF 
injection suggested,  furthermore, that  both  intact and  de- 
graded EGF were secreted. 
Degradation, via the lysosomal system, of proteins endo- 
cytosed by hepatocytes as well as other cell types has been 
extensively documented (4-6). Less well recognized, however, 
1  Abbreviation  used in this paper. EGF, epidermal growth factor. 
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is the transcellular route by which some proteins (e.g., dimeric 
immunoglobulin A [IgA]) are endocytosed from plasma and 
later delivered intact to bile. For this process we have proposed 
a second pathway, i.e., the "direct" or nonlysosomal pathway, 
utilizing "shuttle" vesicles passing from the sinusoidal surface 
of  the hepatocyte to the bile canaliculus (7); we have presented 
morphological and cytochemical evidence for the operation 
of this pathway in the transport of IgA (8) and insulin (9). 
Further support for the direct pathway was recently reported 
by Schiff et at. (10), who found that inhibition of lysosomal 
enzymes with leupeptin had no effect on the biliary secretion 
of IgA. 
The aim  of the present experiments was twofold: (a) to 
delineate the transport pathway(s) and ultimate disposition of 
the EGF taken up by rat liver and (b) to determine the effects 
on EGF transport of lysosomal inhibition with chloroquine. 
Chloroquine was selected to perturb the lysosomal pathway 
because it  has been  shown to  inhibit  degradation of both 
1259 exogenous and endogenous protein by isolated rat hepatocytes 
(11)  and specifically  inhibits EGF degradation in cultured 
hepatocytes (12) and other cells (13-16)  without inhibiting 
uptake (14-16). Chloroquine accumulates in hepatocytic ly- 
sosomes (17, 18) and is thought to inhibit lysosomal enzymes 
by elevating intralysosomal pH (l 9). 
If a direct pathway, independent of the lysosomal system, 
is the means by which undegraded EGF reaches bile,  then 
inhibition of the lysosomal pathway should result in secretion 
of less degraded EGF without affecting the amount of im- 
munoreactive EGF in bile. 
MATERIALS  AND  METHODS 
Preparation  of 1251-EGF:  EGF purified from mouse submaxillary 
glands (20, 21) was kindly supplied by Dr. Denis Gospodarowicz, University 
of California, San Francisco. The EGF was radiolabeled with '2~I-Na (Amer- 
sham Corp.,  Arlington Heights,  IL) by the chloramine-T  method  (22, 23). 
Unreacted ~2~I-Na  was removed by adsorption on a Sephadex G-25 column, 
and the ~2SI-EGF was eluted in the void volume. The 125I-EGF  bad a specific 
activity of ~ 1 mCi/nmol and was >90% immunoprecipitable  with a specific 
antiserum (see  below). 
Uptake of T251-EGF:  Procedures  for the injection of  labeled EGF have 
been described in detail elsewhere (2). A midline abdominal incision was made 
in male Sprague-Dawley rats under pentobarbital  anesthesia. In some rats the 
common  bile duct was cannulated with PE- 10 tubing to allow for bile collection. 
30-50 uCi of ~251-EGF was injected into the portal vein; at selected time points 
a blood sample was taken from the vena cava, and the liver was perfused with 
cold PBS. The liver was then removed, blotted, weighed, and homogenized in 
PBS, and  the radioactivity  of an aliquot  of homogenate  was counted  in a 
gamma counter. 
In studies with chloroquine, chloroquine diphosphate (Sigma Chemical Co., 
St. Louis, MO), was dissolved in saline and injected intraperitoneally  (50 rag/ 
kg in 0.5-0.8  ml saline) at 120 and 60 min before injection of EGF. Controls 
received an equal volume of saline. In some rats the bile duct was cannulated 
and bile was collected for 50 rain;  the remainder  were sacrificed at 30 rain 
postinjection and their livers were processed for autoradiogmphy. 
Autoradiography:  Methods of fixation and processing of liver tissue 
for light microscopic  autoradiography  were described  in an earlier  study  of 
EGF transport by rat liver (2). Thin sections (900 ~,) were cut from the same 
tissue blocks used in that previous study. Therefore, the previously published 
data on specificity of uptake and clearance rates applies to these experiments 
as well. Thin sections were also cut from identically processed blocks of liver 
from three cbloroquine-treated  and two saline-injected rats at 30 rain after 12~I- 
EGF injection.  Sections were  mounted on  parlodion/carbon coated  nickel 
grids, overlaid with llford L-4 emulsion (Ilford Ltd., Essex, UK) using the loop 
technique (24), exposed for 3-7 wk, developed in Kodak D-19 (Eastman Kodak 
Co., Rochester, NY), stained with lead citrate, and examined in a Philips 300 
electron microscope (Philips Electronic Instruments, Inc., Mahwah, NJ) oper- 
ating at 60 kV. For quantitation  of autoradiographic grains, micrographs were 
taken  randomly and  printed  at  a  final  magnification  of x  35,000.  Grain 
distribution  was determined  by the method of concentric circle analysis (9) as 
described previously (25). 
Cytochemistty:  Tissue for cytochemical demonstration  of lysosomal 
enzymes was immersed  for 30  min in the paraformaldehyde-giutaraldehyde 
fixative used for perfusion.  After washing overnight  in bicarbonate  buffer, it 
was chopped into 50-100 um sections and incubated for arylsulfatase according 
to Goldfischer's (26) procedure,  or for acid phosphatase  with either the lead 
method of Barka and Anderson (27) or the CeCI2 technique  of Robinson and 
Karnovsky  (28). Chloroquine-induced  multilamellated  structures  showed re- 
action product with all three procedures. 
Analysis of Bile:  Bile  from chloroquine-treated  or saline-injected rats 
was collected into preweighed tubes at 10-rain intervals. Total radioactivity was 
measured  in a Beckman Gamma 8500 counter (Beckman  Instruments,  Inc., 
Fullerton, CA) and activity per gram bile was calculated. 
For  immunoprecipitation,  duplicate  samples  (20  ul  each)  of bile  were 
incubated overnight at 4"C with a  1:100 dilution of rabbit antiserum to mouse 
EGF (Bethesda Research  Laboratories,  Gaithersberg,  MD) or normal rabbit 
serum.  S. aureus with protein  A (Zymed Laboratories, Burlingame, CA) was 
added to each sample and incubated for 1 h at 4"C. Total activity was counted 
and samples were centrifuged (Beckman Microfuge); pellets were washed three 
times with PBS and counted. After subtraction of  the corresponding nonspecific 
radioactivity of each sample precipitated  by normal serum (never more than 
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5%), the remaining radioactivity in the pellet represented immunoreactive  ~2~I- 
EGF. 
For separation  of intact  EGF from degradation  products, chromatography 
columns (1 x  30 cm) were prepared with Sephadex G-50 hydrated in a buffer 
containing  4 M urea,  I M acetic acid, and 0.1% Triton X-100. The columns 
were eluted with the same buffer and 1-ml  fractions were collected and counted. 
For isolation of  biologically active EGF from bile, u~I-EGF-containing bile was 
fractionated on identical G-50 columns, but was equilibrated and eluted with 
PBS rather than the urea/acetic acid buffer. The peak representing presumably 
intact  EGF was then dialyzed for 3 h against Medium  199 and subsequently 
incubated with primary monolayer cultures of rat hepatocytes. 
Uptake of Bile-derived 1251-EGF by Hepatocyte Cultures: 
Primary monolayer  cultures of  rat bepatocytes were prepared at the Cell Culture 
Core Facility of the Liver Center, University of California, San Francisco, by 
in situ peffusion of the rat liver with collagenase followed by passage through 
an elutriator  to yield a cell suspension of -98% hepatocytes (29). Viability of 
the cell suspension was evaluated by trypan blue exclusion. Cells were plated 
on collagen-coated 35-mm petri dishes in Medium  199 OR supplemented with 
antibiotics,  hormones, and  1%  normal rat  serum, and  reached  confluence 
within 24 h after plating. 
For uptake studies, the medium was removed, and cultures were incubated 
for I h at 37°C with fresh medium containing: (a) ~25I-EGF used for intraportal 
injection, (b) ~2SI-EGF  isolated from bile, or (c) t2~I-EGF  isolated from a mixture 
of  the original 12~I-EGF  and unlabeled bile. A 500-fold excess of unlabeled EGF 
was added to some cultures. The cultures were rinsed three times with ice-cold 
PBS and scraped, and their radioactivity was measured. Uptake was expressed 
as the percentage of initial radioactivity that was retained by the cells. 
RESULTS 
Electron  Microscopic Autoradiography 
Analysis of autoradiograpbic  grains  on  electron  micro- 
graphs demonstrated a  sequential change in association of 
grains with the plasma membrane, endocytic vesicles, multi- 
vesicular bodies, and lysosomes (Table I). Although 40-45% 
of the  grains  were  associated  with other  organdies,  these 
values did not change with time, and their significance is at 
present unknown. 
At 3 min grains were primarily associated  with endocytic 
TABLE  I 
Percentage Distribution of Auloradiographic Grains in 
Hepatocytes after Intraportal Injection of 12SI-EGF* 
Organelle category 
Controls 
Chloro- 
quine 
treated 
Time after injection (m/n) 
3  15  30  90  30 
% 
Plasma membrane  19.0  8.6  6.8  5.6  4.5 
Endocytic vesicles  14.1  5.8  3.1  2.1  0.7 
Multivesicular bodies  22.1  30.1  34.0  12.7  30.0 
Secondary lysosomes  2.0  3.5  10.2  28.7  2.5 
Multilamellated struc  .....  12.4 
tures 
Golgi-rich area  1.9  6.7  4.2  5.6  0.9 
Smooth endop[asmic  26.5  23.9  30.8  30.0  32.3 
reticulum 
Rough endoplasmic re-  3.2  3.4  2.0  3.0  4.6 
ticulum 
Mitochondria  7.6  10.1  6.5  9.1  7.5 
Nuclei  0.4  0.5  0.4  0.5  1.3 
Other*  3.0  2.0  1.9  2.5  3.2 
* Values are means of percentages based on -9,000 grains from over 1,000 
micrographs (fields), representing two control rats for each time point and 
three chloroquine-treated rats. 
* Endothelial cells, Kupffer cells, extracellular space, and cytoplasm with no 
identifiable organelles. FIGURES  1 and 2  Fig.  1:10  min after intraportal injection of 12SI-EGF, autoradiographic grains are sometimes found at the bile 
canalicular surface of the  hepatocyte. Several small vesicles are also apparent in this micrograph; grains are associated with at 
least four of them (arrowheads). BC, bile canaliculus.  Bar,  1 /~M.  x  37,500. Fig.  2: Chloroquine treatment; 30 min after 12SI-EGF 
administration. In addition to their association with multilamellated structures (autophagic vacuoles, AV), grains are occasionally 
seen over small vesicles near the bile canaiculus (arrowhead). BC, bile canaliculus. Bar, 1 u,m. ×  37,800. 
pits and/or vesicles at the sinusoidal surface of  the hepatocyte. 
15  min  postinjection, grains  were associated with multive- 
sicular bodies usually_located near Golgi-rich areas of hepa- 
tocytes, whereas  by  30  min,  labeled  multivesicular bodies 
were found in the pericanalicular area of the hepatocyte. The 
association of grains with multivesicular bodies peaked at 30 
min postinjection, then declined as the association of grains 
with secondary lysosomes increased steadily through 90 rain 
(Table I). 
These data provide evidence for the usual pathway of entry 
of endocytosed EGF into a  lysosomal compartment. How- 
ever, at 10 min postinjection, grains were also found clustered 
around the bile canaliculus (Fig.  1), suggesting  a more rapid 
nonlysosomal  transport  pathway.  Nevertheless,  endocytic 
"shuttle" vesicles,  analogous to  insulin/horseradish  peroxi- 
dase- or IgA-containing vesicles (8, 9) could only occasionally 
be resolved (Fig.  1). In an attempt to enhance EGF transport 
by this pathway, the lysosomotropic agent, chloroquine, was 
administered to rats prior to injection of EGF; autoradiogra- 
phy of the liver at 30 min postinjection and analysis of bile 
from these animals were performed. 
In hepatocytes from chloroquine-treated rats, many large, 
multilamellated structures containing cytoplasmic inclusions 
were present (Fig. 2). The lysosomal nature of these multila- 
mellated structures was demonstrated by cytochemical local- 
ization  of arylsulfatase and  acid  phosphatase  within  them 
(data not shown). The presence of these lysosomal enzymes 
in  chloroquine-induced multilamellated structures has  also 
been demonstrated by other methods (30,  31).  At  30 min 
after the intraportal injection of ~25I-EGF, autoradiographic 
TABLE  II 
Morphometry of Chloroquine-treated Rat Liver* 
Component  Cbloroquine  Control 
% 
Multilamellated structures  3.5 _  0.4  0.0 
Secondary lysosomes  0.5 ___ 0.1  0.6 ___ 0.1 
Multivesicular bodies  0.6 __+ 0.1  0.7 _+ 0.1 
Mitochondria  19.9 +  0.6  20.7 _+ 0.6 
Cytoplasm  62.7 +  1.8  68.1  _+ 1.5 
Morphometric analysis of livers from chloroquine-treated and control rats 
were performed according to the method of Weibel el al. (32). 90 micro- 
graphs (fields), representing three rats from each group,  were used in this 
analysis. 
* Values expressed as percentage of volume of component per unit volume 
total hepatic tissue (mean 4- SEM). 
grains in chloroquine-treated rats were associated with both 
multivesicular bodies and multilamellated structures (Table 
I,  Fig.  2).  Morphometric analysis (32) indicated that,  as a 
result of chloroquine treatment, the volume density of the 
total lysosomal compartment (secondary lysosomes plus mul- 
tilameUated  structures) increased by 3.5%  (Table II).  This 
increase in volume density was accompanied by a concomi- 
tant decrease in cytoplasmic volume. Even though the volume 
density of the  total lysosomal compartment increased,  the 
chloroquine-treated rats  had  approximately the  same  per- 
centage of autoradiographic grains associated with this com- 
partment as the controls; however, of these grains, 80% were 
associated with multilamellated structures rather than second- 
ary lysosomes (Table I).  The distribution of grains  among 
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FIGURES 3-5  Fig.  3: Elution profile of ~2~I-EGF  fractionated on a Sephadex G-50 column in 4 M urea, 1 M acetic acid, and 0.1% 
Triton X-100.  (a) Starting  material,  i.e.,  freshly iodinated EGF. The batch  used  in this particular experiment was only -70% 
immunoprecipitable with anti-EGF.  (b) Starting  material  incubated with unlabeled bile at 37°C  for 40 min. (c) Bile  collected 
between 30 and 40 min after intraportal injection of 12SI-EGF. In each case the middle peak  represents  intact EGF. Fig. 4: Total 
and immunoprecipitable radioactivity in bile collected over a period of 50 rain. 0, total activity--control (n -  4); &, total activity-- 
chloroquine-treated (n = 5); O, immunoprecipitable activity--control (n = 4); A, immunoprecipitable activity, chloroquine-treated 
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same in control and chloroquine-treated rats. 
Analysis of Bile 
The amount and  form of radioactivity secreted into bile 
was used as an indicator of the metabolism of z25I-EGF by 
liver. Therefore, it was necessary to establish that there was 
no degradation of 125I-EGF  as a result of its contact with bile, 
and that any alteration of its form could only result from its 
transport through the liver. 
Labeled bile from control rats, collected between 30 and 40 
min after the intraportal injection of 125I-EGF, was fraction- 
ated on a  Sephadex G-50 column in 4  M  urea,  1 M  acetic 
acid, and 0.1%Triton X-100. Its elution profile was compared 
with those of z:5I-EGF which had been incubated with unla- 
beled bile for 40 min at 37"C and of ~25I-EGF that had never 
been in contact with liver or bile. The elution profiles of the 
~25I-EGF starting material and the  12~I-EGF incubated with 
unlabeled bile were virtually identical (Fig.  3, a  and b).  The 
middle peak, representing intact EGF, accounted for most of 
the radioactivity (61-68%) eluted from the column. The void 
volume peak, containing larger molecules (>10,000 mol wt) 
had ~5% of the eluted radioactivity whereas the total volume 
peak, consisting of lower-molecular-weight breakdown prod- 
ucts, tyrosine residues, or free J25I, accounted for 20-28% of 
the eluted radioactivity. In contrast, the elution profile of the 
labeled bile (Fig.  3 c) showed that >90% of the eluted radio- 
activity was associated with the total volume peak, indicating 
that most of the ~25I-EGF secreted into bile at this time had 
been degraded  as  a  result  of its transhepatocyte transport. 
These results demonstrate that even prolonged contact with 
bile does not cause degradation of t25I-EGF, and that there- 
fore, alterations in the structure of the J25I-EGF secreted into 
bile are due to the metabolic activity of hepatocytes. 
Bile  collected over  10-min intervals after the  intraportal 
injection of ~25I-EGF was analyzed for its radioactive content 
by measurement of both total and immunoprecipitable radio- 
activity. Total radioactivity secreted per gram bile was signif- 
icantly reduced in chloroquine-treated rats; at 40 min it was 
<20%  that secreted by controls (Fig.  4),  although total bile 
output did not significantly decrease (0.868 +  0.05 g/50 min 
in controls vs. 0.716 _+ 0.27 g/50 min in chloroquine-treated 
rats). The percentage of immunoprecipitable radioactivity in 
each bile sample was compared for chloroquine-treated versus 
control rats (Fig. 5). In chloroquine-treated rats, immunopre- 
cipitable radioactivity peaked at 30  min postinjection,  and 
accounted for 55 % of the total radioactivity secreted, whereas 
in  controls, immunoprecipitable radioactivity peaked at 20 
min and represented only 35% of the total. However, when 
the  amount  of immunoprecipitable  radioactivity (the  per- 
centage immunoprecipitable times the total counts per min- 
ute/gram) was calculated, it was apparent that this value was 
virtually the same in both groups of rats (Fig.  4).  Thus,  in 
control  rats,  degradation  products  accounted  for the  great 
majority of the radioactivity secreted into bile, especially at 
later time points. 
The radioactivity in blood and liver of chloroquine-treated 
versus  control  rats was compared at  50  min  postinjection 
TABLE III 
Radioactivity in Liver and Blood 
Control  Chloroquine 
(n =  4)  (n =  6) 
Liver (cpm x  lO-6/g)  1.75 4- 0.32  3.90 4- 0.10 
Blood  (clam x  lO-6/ml of whole  0.42 +  0.I0  0.20 4- 0.07 
blood) 
Blood samples were collected 50 min after intraportal injection of 12SI-EGF. 
The entire liver was removed, blotted, weighed, and homogenized, and an 
aliquot was counted. Blood was allowed to clot and an aliquot of serum was 
counted. 
(Table III). Radioactivity per gram of  liver more than doubled, 
whereas radioactivity in blood decreased relative to controls, 
as a result of chloroquine treatment. All of these data taken 
together suggest that chloroquine inhibits degradation of t251. 
EGF;  this  results in  accumulation  of radioactivity in  liver 
with a concomitant decrease in release of radioactive degra- 
dation  products into both the blood and bile,  whereas the 
secretion of undegraded t25I-EGF is unaffected. 
Uptake of t2SI-EGF Derived from Bile 
Although some of the ~2~I-EGF  in bile was immunoprecip- 
itable,  implying an  intact  molecule, this  in  itself does  not 
indicate biological activity. To further characterize the pre- 
sumably unaltered EGF secreted in bile, it was isolated and 
incubated with primary cultures of rat hepatocytes. 
For this purpose ~25I-EGF-containing  bile samples collected 
from control rats were pooled (composite immunoprecipita- 
bility ---10%) and fractionated on a  Sephadex G-50 column 
in PBS.  The middle peak, corresponding to intact EGF, was 
dialyzed against Medium  199,  using dialysis tubing with  a 
molecular weight exclusion limit of 2,000. <4% of the radio- 
activity was  lost  through  the  dialysis  membrane.  ~2~I-EGF 
mixed  with  unlabeled  bile  was  similarly  fractionated  and 
dialyzed. 
Primary cultures of rat hepatocytes were incubated with 
the above column-derived preparations of ~25I-EGF, as well 
as with '25I-EGF starting material. A 500-fold excess of unla- 
beled EGF was also added to some of the cultures. After 1 h 
at 37"C, the cultures were rinsed, the cells were scraped free, 
and  the  radioactivity  retained  by  the  cells  was  measured 
(Table IV). 
In order to take into account the variable concentrations of 
~25I-EGF in column-derived material, some of the  125I-EGF 
starting material and some of the ~25I-EGF mixed with unla- 
beled bile were further diluted with Medium 199 to a concen- 
tration of radioactivity equal to that of the ~25I°EGF  isolated 
from  bile.  There  was  no  difference  in  the  percentage  of 
radioactivity  taken  up  by  hepatocytes  incubated  with  the 
diluted versus undiluted preparations. Therefore, these results 
have been combined under each category of labeled material 
in Table IV. 
The results of this experiment indicate that  ~25I-EGF iso- 
lated from bile was specifically taken up by cultured bepato- 
cytes with an efficiency slightly less than that shown for the 
starting material either alone or mixed with unlabeled bile. 
(n =  5).  Error bars =  standard error of the mean. Total radioactivity in control  bile continued  to increase for 40 min whereas  in 
chloroquine-treated  rats  it  remained  relatively  constant  at  a  much  reduced  level.  Except  for  a  small  difference  at  20  min, 
immunoprecipitable  activity in the two groups was identical.  Fig. 5: Immunoprecipitable  radioactivity secreted in bile, expressed 
as a percentage of the total. A, chloroquine-treated  (n =  5); 0, control (n =  4). Error bars =  standard error of the mean. 
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Uptake of Bile-derived EGF by Cultured Hepatocytes 
% Spe- 
cific 
Labeled material  %  Bound  binding 
12SI-EGF in Medium 199 (n = 9)  12.2 -  0.6 ) 
IzSI-EGF in Medium 199 +  x500 cold  I  92.6 
EGF (n =  9)  0.9 --- 0.2 
12SI-EGF from bile (n =  6)  10.0 +  0.8 "[ 
12SI-EGF from bile +  x500 cold EGF  I  92.0 
(n =  6)  0.8 +  0.2 
~251-EGF mixed with bile (n =  3)  13.7 +  0.7 ] 
12SI-EGF mixed with bile +  x500 cold  t  85.7 
EGF (n =  3)  2.1 +  0.2 
Bile  from IZSl-EGF-injected rats or 12SI-EGF mixed with unlabeled  bile was 
eluted  from  a  Sephadex  G-50  column  with  PBS. The  middle  peak was 
dialyzed  against  Medium  199.  In  addition,  IzSI-EGF that  had  not  been  in 
contact with bile was added to Medium  199. Some of each  of these  latter 
two preparations  were further diluted with Medium 199 to a concentration 
of radioactivity equal to that of the 12SI-EGF  isolated from bile.  1.0 ml of each 
of these  preparations was added to 35-ram culture dishes  containing 48-h 
primary cultures of rat  hepatocytes. After incubation  at 37"C  for I  h,  the 
cultures were washed three times in ice-cold PBS, and the cells were scraped 
from the dishes and counted. Values represent mean _+ SEM. 
Neither the  presence  of incidental  biliary  components  in 
column-derived material, nor variable concentrations of I25I- 
EGF, could account for this less efficient uptake. 
DISCUSSION 
The experiments reported here provide further support for 
the hypothesis that some proteins traverse the hepatocyte by 
a pathway independent of the lysosomal system and are thus 
secreted intact into bile. When 125I-EGF  is injected intrapor- 
tally into rats, both degraded and intact protein is demonstra- 
ble in the bile.  Although immunoprecipitable radioactivity 
peaks at 20 min, that associated with degradation products 
does not reach a peak until 40 min postinjection. Further- 
more, the intact EGF isolated from bile is specifically taken 
up by cultured hepatocytes, indicating that it is still recogniz- 
able by the  EGF receptor. When  the  lysosomal system is 
inhibited  with  chloroquine,  secretion  of degraded  EGF  is 
significantly decreased, whereas the amount of intact EGF 
appearing in bile remains unchanged. 
The actual amount of intact EGF that reaches the bile is 
-4% of the injected dose (20% of the injected radioactivity is 
secreted into bile over 90 rain, of which 20% is immunopre- 
cipitable  [2]).  This  percentage is  slightly  higher than  that 
reported for asialoglycoproteins secreted intact into bile over 
a 2-h period (33). Because this percentage is not quantitatively 
significant,  the nonlysosomal pathway has been overlooked 
as having any physiological significance for plasma-derived 
proteins normally degraded by liver. 
Because the amount of intact EGF in bile is small relative 
to the injected dose, the possibility exists that a nonspecific 
uptake and transport process (fluid-phase endocytosis) might 
account for the appearance of intact EGF or other proteins 
in bile. However, Schiff et al. (10) have reported that, in the 
case of two proteins that are taken up nonspecifically by rat 
liver (fetuin and human serum albumin), < 1% of  the injected 
dose of these proteins appears intact in bile over a period of 
150 rain. Therefore, it does not appear likely that nonspecific 
fluid-phase endocytosis can account for the majority of the 
intact EGF in bile. 
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The operation of the nonlysosomal pathway most likely 
involves specific,  receptor-mediated endocytosis, as does the 
operation of the  lysosomal  pathway.  Because  there  is  no 
evidence for more than one class of EGF receptor on liver 
membranes (34),  the sorting of EGF into the two separate 
pathways probably takes place subsequent to the formation 
of the EGF-receptor complex. The mechanisms which regu- 
late the  selection of transport pathway are  at  present un- 
known. 
The best characterized nonlysosomal transport pathway in 
the rat hepatocyte is that used for the transport of rat dimeric 
IgA  (8,  10). However,  the  kinetics  of its  transhepatocyte 
transport appear to be different from those of EGF. Its peak 
secretion into bile occurs between 30 and 40 min postinjec- 
tion,  and  -67%  of the  injected radioactivity is  eventually 
secreted into bile (150 min) (10), whereas the peak secretion 
of intact EGF occurs at 20 min postinjection, and only 20% 
of the injected radioactivity is secreted into bile over 90 min 
(2).  However, the  apparent discrepancy in  the  kinetics of 
transport of these two proteins probably does not involve the 
operation of the shuttle-vesicle transport system, but rather is 
due to differences in the rate and efficiency  of their uptake by 
liver and other organs. The uptake of even supraphysiological 
doses of EGF appears to be virtually complete on a single 
pass through the liver (2); for IgA it is not (10). Also, whereas 
IgA is taken up from plasma mainly by the liver (10), EGF is 
sequestered by other organs as well (2). 
The use of supraphysiological doses of EGF in these studies 
does not affect the percentage of intact EGF reaching the bile, 
as long as the transport system is not saturated (the highest 
dose used in the present experiments [70 ng], was well below 
the  level of saturation  [3,  35]).  In  other experiments,  we 
compared the transport of physiological with supraphysiolog- 
ical doses of EGF and found the same relative proportions of 
immunoreactive and degraded EGF in bile (35). 
Up to now, morphological demonstration of the "direct," 
nonlysosomal transport  pathway  in  hepatocytes has  been 
inconclusive (8, 9). This is because, as was recently pointed 
out (10), morphological methods lack sufficient sensitivity to 
detect nonlysosomal transport. However, analysis of bile as 
to the amount and form of secreted radioactivity gives much 
better  sensitivity than  morphological  methods  alone,  and 
indicates how transhepatocyte processing affects the molecule 
being transported. Using similar methods, the kinetics of the 
nonlysosomal transport of IgA by rat liver has recently been 
demonstrated (10). The evidence presented here strongly sup- 
ports  the  existence  of a  "direct,"  nonlysosomal transport 
pathway for EGF, as well as  for IgA.  Furthermore, EGF, 
unlike IgA, utilizes a dual transport process. The physiological 
significance of this unusual system of intracellular processing 
is not yet clear. However, the liver's dual role in both con- 
serving and destroying EGF may provide a homeostatic mech- 
anism  for maintaining  EGF levels  in  liver,  bile,  gut,  and 
plasma. 
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